A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Study ID

Protocol Number: 22-0052

More information available at ClinicalTrials.gov: NCT05355753

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers